Thomas O. Daniel (Celgene Corporation)
Chief Scientific Officer Seminar Series
Sponsored by Office of Corporate Relations and Department of Molecular Biology
Thomas O. Daniel, M.D.
EXECUTIVE VICE PRESIDENT
PRESIDENT OF RESEARCH AND EARLY DEVELOPMENT
Dr. Thomas O. Daniel, M.D., has been Executive Vice President, President - Research and Early Development of Celgene Corp., since February 15, 2012. He has been President, Research and Early Development since December 2006. Previously he served as the Chief Scientific Officer at Ambrx Inc., as Vice President, Research at Amgen Inc., and as Senior Vice President of Discovery Research at Immunex. Dr. Daniel currently serves as a member of the Biomedical Science Advisory Board of Vanderbilt University Medical Center. A nephrologist and former academic investigator, Dr. Daniel was previously the K.M. Hakim Professor of Medicine and Cell Biology at Vanderbilt University, and Director of the Vanderbilt Center for Vascular Biology. He formerly conducted research in the Howard Hughes Medical Institute at UC San Francisco, earned an M.D. from the University of Texas, Southwestern, and completed medical residency at Massachusetts General Hospital.
Found in Translation: Paths from Leading Science to Transformative Medicines
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation.
For more information, please visit www.celgene.com.
Free and open to the university community and the public